# Pheno Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pheno-therapeutics

- Industry: Biotechnology
- Headquarters: Edinburgh, UK
- Website: www.phenotherapeutics.com
- Total disclosed funding: $6.5M
- Latest round: Series A (Mar 28, 2019)
- Investors on record: 3

## About

Pheno Therapeutics Limited is focused on developing innovative neuroprotective therapies targeting the GPR17 receptor to address neurodegenerative diseases and improve patient outcomes.Founded in 2020 in Edinburgh, UK, Pheno Therapeutics Limited specializes in neuroprotective therapeutics. The company raised GBP 5 million in a SERIES A funding round on March 28, 2019, with investment from Advent Life Sciences, LifeArc, and Scottish Investment Bank. The CEO is Fraser Murray, and the founders include Neil Carragher and Siddharthan Chandran. The company has completed one deal to date and has a current valuation of GBP 9.412 mn.Pheno Therapeutics develops neuroprotective therapeutics leveraging the GPR17 receptor's biology. The company aims to provide innovative treatments for neurodegenerative diseases and conditions with neuronal damage, specifically targeting multiple sclerosis and other disorders. Their clientele includes pharmaceutical firms, healthcare providers, and research institutions, primarily in North America and Europe, where the demand for advanced neurotherapeutics is increasing.Pheno Therapeutics generates revenue through strategic partnerships and collaborations in the pharmaceutical sector, involving milestone payments, royalties, and structured financial arrangements. Their business model focuses on B2B transactions, collaborating with larger enterprises in healthcare to enhance the reach of their neuroprotective solutions. In the most recent year, the company reported an EBITDA loss of GBP 2,481,890.70.Pheno Therapeutics plans to utilize the GBP 5 million raised in the SERIES A round to fund the search for new drugs aimed at repairing nervous system damage. The company is focused on expanding into new geographical markets, particularly in North America and Europe, to address the growing demand for their neuroprotective therapeutics.

## Funding rounds

- Series A, Mar 28, 2019, $6.5M — Advent Life Sciences, Scottish Investment Bank, LifeArc

## Investors

- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series A
- Scottish Investment Bank — Series A
- LifeArc (https://capitalatlas.ai/funds/lifearc) — Series A